MBX Biosciences, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
MBX Biosciences, Inc. (MBX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $467.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$258.00K, a 132.45% decline year-over-year.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $725.00K.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.00M, a 94.85% increase year-over-year.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.54M, a 171.53% increase year-over-year.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.70M, a 14.86% increase from fiscal 2024.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.35M, a 124.26% increase from fiscal 2023.
- MBX Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.05M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$258.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $467.00K 10-Q · filed 2026-08-06 | $2.47M derived: sum of 3 quarters · filed 2026-08-06 | $4.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $725.00K 10-Q · filed 2026-05-07 | $2.73M derived: sum of 2 quarters · filed 2026-05-07 | $4.28M derived: sum of 3 quarters · filed 2026-05-07 | $5.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.55M derived: sum of 2 quarters · filed 2026-03-12 | $4.34M derived: sum of 3 quarters · filed 2026-08-06 | $2.70M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.34M derived: sum of 2 quarters · filed 2026-08-06 | $692.00K 10-Q · filed 2025-11-06 | $1.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$853.00K 10-Q · filed 2026-08-06 | $176.00K derived: sum of 3 quarters · filed 2026-08-06 | $745.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.65M 10-Q · filed 2026-05-07 | -$619.00K derived: sum of 2 quarters · filed 2026-05-07 | -$50.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.60M derived: sum of 2 quarters · filed 2026-03-12 | $2.76M derived: sum of 3 quarters · filed 2026-03-12 | $2.35M 10-K · filed 2026-03-12 |
| 2024-09-30 | $569.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.73M derived: sum of 2 quarters · filed 2025-11-06 | $1.32M 10-Q · filed 2025-11-06 | $2.64M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $750.00K 10-Q · filed 2025-08-07 | $2.07M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$408.00K 10-Q · filed 2025-05-12 | $914.00K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.05M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | -$275.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |